OncoMatch/Clinical Trials/NCT07216105
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Is NCT07216105 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including FT836 and Cetuximab for non-small cell lung cancer.
Treatment: FT836 · Cetuximab · Trastuzumab — This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 with or without chemotherapy and/or trastuzumab or cetuximab
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Breast Carcinoma
Ovarian Cancer
Endometrial Cancer
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemic therapy
Lab requirements
Blood counts
ANC >1000/µL without growth factor support within 7 days; Platelet count ≥75,000/µL without transfusion support within 14 days
Kidney function
Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method
Liver function
Total bilirubin ≤1.5 × ULN (≤3 × ULN if Gilbert syndrome); AST ≤3 × ULN or ALT ≤3 × ULN (≤5 × ULN with liver metastases); ALP ≤2.5 × ULN (≤5 × ULN with liver or bone metastases)
Cardiac function
Oxygen saturation >90% on room air; cardiac ejection fraction ≥50%
Evidence of adequate organ function as determined by all of the following: ANC >1000/µL without growth factor support within 7 days; Platelet count ≥75,000/µL without transfusion support within 14 days; Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method; Total bilirubin ≤1.5 × ULN (≤3 × ULN if Gilbert syndrome); AST ≤3 × ULN or ALT ≤3 × ULN (≤5 × ULN with liver metastases); ALP ≤2.5 × ULN (≤5 × ULN with liver or bone metastases); Oxygen saturation >90% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- University of Southern California · Los Angeles, California
- University of Minnesota Masonic Cancer Center · Minneapolis, Minnesota
- Thomas Jefferson University, Sidney Kimmel Cancer Center · Philadelphia, Pennsylvania
- M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07216105 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify